Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

Phase 1

  • TBI-223
    • TBI-223 / Oxazolidinone
    Institute of Materia Medica
  • PK of First-Line Drugs in Children <5kg
    • Isoniazid / Rifampin / Pyrazinamide / Ethambutol Pediatric HRZE

Phase 2

  • Sutezolid
    • Sutezolid / Oxazolidinone
    Bill & Melinda Gates Medical Research Institute
  • TBA-7371
    • TBA-7371 / DprE1 Inhibitor
    Foundation for Neglected Disease Research, Bill & Melinda Gates Medical Research Institute

Phase 3

  • SimpliciTB
    • Bedaquiline / Pretomanid / Moxifloxacin / Pyrazinamide BPaMZ
    PanACEA, Mylan
  • ZeNix
    • Bedaquiline / Pretomanid / Linezolid BPaL
    Mylan
  • Nix-TB
    • Bedaquiline / Pretomanid / Linezolid BPaL
    Mylan

Phase 4

  • Optimized First-Line Drugs in Children >5kg
    • Ethambutol
    • Pyrazinamide
    • Isoniazid
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance Names Dr. Daniel Everitt Vice President and Chief Medical Officer
Jane Griffiths Joins TB Alliance Board of Directors
TB Research Funding Continues to Fall Short

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2020 The TB Alliance. All Rights Reserved. Site by Darby Communications